Long-acting antiviral medications are transforming HIV prevention and care, requiring only minimalistic dosing. But as the use of lenacapavir expands, scientists are probing a critical question: If ...

A recent study confirms lenacapavir's effectiveness against HIV and highlights the capsid as a promising drug target despite resistance.

The tiny shell protecting the HIV virus resembles a slightly rounded ice cream cone, but there is nothing sweet about it.

Scientists at the Electron Bio-Imaging Centre (eBIC) at Diamond Light Source, in the U.K., have harnessed a new technique, using cryo-electron tomography (cryoET) and subtomogram averaging (STA) to ...

In order for HIV to replicate, the viral genome must enter into the cell nucleus and integrate into the host cell chromosome. Previous work suggests that the entry proceeds through nuclear pore ...

Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between capsid protein (p24) subunits in hexamers. Surface plasmon resonance sensorgrams ...

Researchers revealed that HIV integrase forms structural filaments within the viral capsid, enabling viral infectivity. The discovery uncovers a new drug target, opening possibilities for ...

The nonprofit Finding Hope for Frizzle aims to initiate a clinical trial of the gene therapy for FRRS1L disease in the second half of 2026.

A new technique using electron tomography and subtomogram averaging at Diamond’s electron Bio-Imaging Centre (eBIC), has solved the structure of the HIV capsid alone and in complex with host factors.